September 15, 2016 09:13 ET

Endonovo Establishing Its Footprint in Non-Invasive Bioelectronic Medicine Space --

REDONDO BEACH, CA--(Marketwired - Sep 15, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces an article covering Endonovo Therapeutics' (OTCQB: ENDV) novel, non-invasive and NASA-developed bioelectronics technology. Also included is an executive interview with Endonovo CEO Alan Collier.

The concept of electroceuticals, often called bioelectronics, dates back nearly three centuries to Italian physician, physicist and biologist Luigi Aloisio Galvani. Even though we see applications today, including the basic example of pacemakers, the scientific community is only beginning to scratch the surface of the opportunity at hand to modulate the body's neural superhighway to treat and prevent diseases and conditions.

In naming their new joint venture company Galvani Bioelectronics, GlaxoSmithKline and Google parent Alphabet's life sciences unit paid tribute to the man widely credited for discovering animal electricity and pioneering bioelectromagnetics. In the world's most ambitious efforts in the electroceutical space to date, the two companies have agreed to spend $715 million across seven years to develop tiny, implantable devices aimed at modifying electrical nerve signals. The investment speaks volumes to the potential therapeutic benefits of bioelectronic devices.

While several companies are addressing implantable devices, Endonovo Therapeutics is taking a different route in the electroceutical space. The company is focused on non-invasive devices for multiple applications, namely to prevent vital organs from failing by controlling inflammation through its Immunotronics technology and growing more potent stem cells with its Cytotronics platform.

To read the article and see the interview, please click here:

To watch the interview alone on YouTube, use this link:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information